Introduction
protein from the Rel group [which includes p65 (RelA), c-Rel and RelB].
1,2 Various stimuli, including Nuclear factor-kappaB (NF-B) is a ubiquitous dimeric transcription factor that exists in the cytosol ischemia, cytokines, hypoxia, free radicals and oxidants, lipopolysaccharide (LPS), activators of procomplexed to an inhibitory kappaB (I B) monomer. NF-B complexes consist of either a p50 (NF-B1) tein kinase C, ultraviolet radiation, and viruses activate NF-B. 1 Activated NF-B translocates to the specific phosphorylation sites of I B , 4 another approach to repress NF-B activity has been the the nucleus and binds to specific DNA binding sites, called B, present within the promoter regions of expression of transdominant mutant I B proteins defective in phosphorylation. A mutant of human various genes including those encoding p65, I B , tumor necrosis factor-(TNF-), interleukin (IL)-2, I B having the serine residues at positions 32 and 36 substituted by glycine and alanine, respectively, IL-6, IL-8, interferon (IFN)-, inducible nitric oxide synthase (iNOS), and several adhesion molecules. 1, 2 was shown to repress activation of all NF-B signaling in NTera-2 cells. 18 Similarly, a cDNA with Activation of NF-B is controlled by site-specific phosphorylation and ubiquitination of I B proteins both serines replaced by alanines (I B S32A,S36A ) was used to abrogate NF-B activation in Jurkat Tthat target I B for proteasome-mediated degradation. 3 There are currently seven known I B cells. 19, 20 Transgenic expression of a truncated I B lacking these phosphorylation sites in a T-cell-speisoforms: I B , I B , I B , Bcl-3, I B , I B-R, and I B-L, 2 and each is capable of binding all possible cific manner resulted in profound inhibition of NF-B activity in thymocytes. 21 NF-B dimers, though with variable avidity. 2 Of these different I B proteins, I B and I B have
In order to determine whether expression of a transdominant mutant I B abrogates NF-B acbeen studied most extensively, and are thought to be the key regulators of NF-B nuclear translocation.
tivation specifically in the heart, we created transgenic mice with cardiac-specific expression of Phosphorylation of serine residues at positions 32 and 36 is critical for ubiquitination and degradation I B S32A,S36A
. The -MyHC promoter was chosen to drive expression of I B S32A,S36A since this promoter of I B 4 with consequent release and nuclear migration of NF-B. I B is also regulated in an directs high level, cardiac-specific gene expression in a position-independent, copy-number-dependent analogous manner. 5 However, the signaling events leading to degradation of I B in the myocardium manner. 22,23 TNF-and LPS were selected as stimuli for the present study because of their potency in and its role in myocardial NF-B activation are virtually unknown.
eliciting NF-B activation as well as their physiological relevance in orchestrating NF-B sigMounting evidence indicates that NF-B plays a major role in various cardiac pathophysiologic naling. [24] [25] [26] The results demonstrate that I B S32A, S36A transgenic mice exhibit normal cardiac morprocesses, including ischemic preconditioning, 6 congestive heart failure (CHF), 7 unstable angina phology and histology and that the expression of the mutant I B completely blocks NF-B activation by pectoris, 8 atherogenesis and expression of adhesion molecules, 9 cardiac allograft rejection, 10 and apoboth TNF-and LPS. These mice provide an in vivo system, for the first time, to study and conclusively ptosis. 11 Although the etiologies of these diverse clinical entities are varied, the signal transduction determine the role of NF-B in specific cardiac pathophysiological states. cascades activated during these processes intersect at the activation of NF-B. Furthermore, experimental evidence suggests that activation of NF-B by signaling pathways that involve TNF-and
Materials and Methods
LPS occurs during the genesis of a wide spectrum of cardiac pathophysiological states, including conThe present study was performed in accordance with the guidelines of the Animal Care and Use gestive heart failure and apoptosis. Unequivocal assessment of the functional contribution of NF-B Committee of the University of Louisville School of Medicine and with the Guide for the Care and Use to these processes, however, has been impeded by the lack of means to achieve selective inhibition of of Laboratory Animals (Department of Health and Human Services, Publication No.
[NIH] 86-23). this transcription factor in vivo.
Although various pharmacologic inhibitors of NF-B are available for in vivo use, none of these has sufficient specificity to provide conclusive evidGeneration of I B S32A,S36A transgenic mice ence of NF-B function. 12, 13 A number of investigators have accomplished gene knockouts of
We constructed a transgene for the expression in the murine heart of a transdominant human I B several of the NF-B encoding genes. [14] [15] [16] [17] However, NF-B signaling was not completely abrogated in cDNA (with serine residues at positions 32 and 36 replaced by alanine, I B S32A,S36A
). The human these mice, [14] [15] [16] probably due to the functional redundancy of NF-B subunits. Furthermore, RelA I B S32A,S36A cDNA (a kind gift from Dr John Hiscott, Department of Biochemistry, McGill University, (p65) knockout mice die in utero due to widespread liver apoptosis. 17 Subsequent to the identification of Montreal, Canada) was released from the original ) was subcloned between the 5.5 kb -MyHC promoter and the 736 bp human growth hormone (Hgh) polyadenylation signal. The cDNA was released from plasmid pSVK3 by excision with Sma I and cloned into the Sal I restriction site of the -MyHC vector. 22 The transgene was excised from the plasmid by restriction with Not I and used for pronuclear microinjection. The 4.3 kb fragment from the -MyHC promoter and the 2.1 kb fragment containing a portion of the I B S32A,S36A cDNA were identified by Southern analysis following digestion with Bgl II and using, as probes, an 800 bp complementary sequence from the -MyHC promoter (probe 1) and the entire I B S32A,S36A cDNA (probe 2), respectively (lower panel). Five founders with 1, 2, 7, 4, and 7 copies of the transgene were identified. We were unable to obtain any offspring from the single copy number founder. The results of the Southern analysis were consistent with the results of PCR screening (Materials and Methods).
plasmid (pSVK3) 20 by restriction digestion with Sma 30 g of genomic DNA was digested with Bgl II, I and subcloned between the 5.5 kb -MyHC prorun overnight on 0.8% agarose gel, transferred onto moter and the 736 bp human growth hormone nitrocellulose membrane and probed with DNA polyadenylation sequences 22 (Fig. 1) . Transgenic fragments, one complementary to a portion of the mice were made by pronuclear microinjection of -MyHC promoter (Probe 1), and the other comthe isolated purified linear transgene into the male plementary to I B (Probe 2). The transgenic foundpronuclei of fertilized mouse oocytes (FVB/N strain) ers were identified by the presence of the transgeneat the transgenic core facility at the University of specific 2.1 kb band (Fig. 1) . The copy number Cincinnati according to established methods. 27 The of the transgene in each line was determined by founder transgenic mice were genotyped by PCR, comparing the intensity of endogenous bands of using an -MyHC-specific primer (5′-AAGCCTknown copy number with bands of similar size AGCCCACACCAGAAATGACAGACA-3′) and an derived from the transgene, using a STORM 840 I B -specific primer (5′-AGTAGCCGCTCCTTCimage analyzer and Imagequant software (Mo-TTCAGCCCGTC-3′). PCR was performed using the lecular Dynamics, Sunnyvale, CA, USA). Founder following steps: 94°C for 7 min, followed by 94°C mice positive for the transgene were bred to derive for 1 min, 63°C for 30 s, and 72°C for 30 s for 35 four (a fifth founder did not produce F 1 ) independent cycles, with a final extension at 72°C for 10 min.
lines, formally designated as TgN(IKBABD)17-Kykj (two copies of transgene), TgN(IKBABD)44-Kykj (seven copies of transgene), TgN(IKBABD)-Southern blot analysis 151Kykj (four copies of transgene), and TgN(IKBABD)159Kykj (seven copies of transTo confirm genotypes and to determine copy number of the transgene in founder mice, approximately gene).
Histologic analyses
immunoblotting. Briefly, 100 g of protein was electrophoresed on an 8% denaturing SDS gel for 7 h Heart wt to body wt ratio (mg/g) was assessed in and transferred to nitrocellulose membranes (Amersham, Piscataway, NJ, USA) overnight at 4°C. The age-(22-28 wk) and sex (male)-matched transgenic and non-transgenic (NTg) mice (n=4 in each membranes were stained with Ponceau S and computer densitometry was used to determine relative group). Mice were euthanized by CO 2 inhalation and the hearts were excised while still beating. loading. The filters were then blocked with 5% nonfat dry milk in TBS [10 m Tris-HCl (pH 7.2), 0.15  Following excision of all extracardiac structures, hearts were incised to expose the cavities, drained NaCl] containing 0.1% Tween 20 (TTBS buffer).
The blot was incubated with primary antibodies of all intracavitary blood, washed in 1× PBS, blotted to remove PBS, and weighed. For histologic against I B and I B (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) at a 1:2000 dilution analyses, following euthanasia, hearts were perfused in situ under pressure (80 mmHg) through for 1 h at room temperature. Blots were washed four times (5 min each) with TTBS buffer at RT and the apex with ice-cold 1× PBS using a 20-gauge needle. This was immediately followed by perfusion incubated with HRP-conjugated goat anti-rabbit secondary antibody (Bio-Rad) at a dilution of 1: with ice-cold cardioplegic solution (25 m KCl, 5% dextrose in 1× PBS) to ensure myocardial re-5000. Signal detection was by enhanced chemiluminescence (ECL) using a NEN Renaissance kit laxation. Fixation was done by perfusion under pressure (80 mmHg) using 4% paraformaldehyde (NEN Life Science Products, Boston, MA, USA). Immunoreactive proteins were visualized by exin 1× PBS, and the hearts allowed to fix further overnight. Next day, the hearts were dehydrated posure of the membrane to X-ray film (X-OMAT-AR, Eastman Kodak), and quantitated using an through a graded series of alcohols and paraffinembedded with apex down, with care taken to image scanning densitometer and Imagequant software (Personal Densitometer SI, Molecular Dyorient them similarly.
Step serial sections were taken every 75 m from apex to base and mounted on namics). The I B and I B signals were normalized to the Ponceau stain signal. slides. Adjacent sections were stained with hematoxylin and eosin and with Masson's trichrome and examined microscopically. The entire procedure, including examination by an experienced pathoElectrophoretic mobility shift assay logist, was done in a blinded manner. Photomicrographs were taken using a Nikon Preparation of nuclear extracts Microphot-FXA microscope (Nikon Inc., Melville, NY, USA) and a digital camera (Kodak DCS 420, Nuclear extracts from ventricular tissue samples were prepared using a modification of a previously Eastman Kodak, Rochester, NY, USA).
described method. 29 The samples were homogenized (Bessman Tissue Pulverizer, Fisher Scientific Co., Pittsburgh, PA, USA) in buffer A [10 m Hepes Western immunoblotting (pH 7.9), 1.5 m MgCl 2 , 10 m KCl, 1 m DTT, 20  leupeptin, and 1 m PMSF]. After a 10-min Tissue preparation incubation on ice, the samples were centrifuged at 1850×g for 10 min at 4°C. The pellets were Murine ventricular tissue samples were hodissolved in buffer B (Buffer A+0.1% Triton X-100), mogenized in buffer containing 50 m Tris-HCl incubated on ice for 10 min, and then centrifuged as (pH 7.5), 5 m EDTA, 10 m EGTA, 10 m benabove. The crude nuclear pellets, washed once with zamidine, 50 g/ml PMSF, 10 g/ml aprotinin, buffer A, were resuspended in buffer C [20 m 10 g/ml leupeptin, 10 g/ml pepstatin A, and Hepes (pH 7.9), 25% glycerol (v/v), 0. P]dATP and T4 polynucleotide kinase (Promega), and purified using a G-25 Sephadex column ies conducted both in vivo and in vitro to examine the activation of NF-B in cultured cells and tissues (Pharmacia Biotech, Piscataway, NJ, USA). The binding reactions were performed in a final volume varies over a wide range (10 ng/ml to 100 ng/ ml). [30] [31] [32] Since calculated in vivo concentrations (deof 10 l containing 8 g of nuclear protein, 10 m Tris-HCl (pH 7.5), 50 m NaCl, 1 m MgCl 2 , rived from total dose used) as low as 40 ng/ml have been shown to activate NF-B, 31 we selected a dose 0.5 m EDTA, 0.5 m DTT, 4% glycerol (v/v), and 1 g Poly(dI-dC)·(Poly(dI-dC). After a 10-min preof 2.5 g/mouse of rm-TNF-administered i.p. (expected to produce a serum concentration of apincubation at 4°C, the labeled probe (approximately 100 000 cpm/reaction) was added to each reaction proximately 145 ng/ml in a 25 g mouse) to activate NF-B. A dose of 4 mg/kg of bacterial LPS has been mixture and incubated for an additional 20 min at 22°C. The DNA-protein complexes were then shown to be adequate to activate NF-B in vivo in several previous studies. 33, 34 In the present study, we separated on 4% non-denaturing polyacrylamide gels in 0.5× Tris borate-EDTA buffer. Gels were selected a dose of 6 mg/kg of LPS to ensure activation of NF-B while avoiding potential lethality. vacuum-dried and exposed to X-ray film at −70°C using an intensifying screen or imaged using a phosphorimager (STORM 840, Molecular Dynamics). Gel supershift and competition assays were Time-course of NF-B activation performed to ensure that the signal was specific for NF-B. For the supershift assays, 0.3 g of anti-p65
The time-course of NF-B activation was determined antibody (Santa Cruz Biotechnology Inc.) was added in six groups (n=2 in each group) of transgenic mice to the reaction mixture immediately after addition (groups VII, IX and XI) and NTg littermates (groups of radiolabeled probe. For the competition assays, VI, VIII and X). All mice received an i.p. injection of 100-fold molar excess of unlabeled NF-B conrm-TNF-(2.5 g in 0.4 ml sterile water). Mice were sensus oligonucleotide or an unlabeled mutated killed 1 h (groups VI and VII), 3 h (groups VIII and NF-B oligonucleotide (Promega) were added into IX) and 6 h (groups X and XI) after the rm-TNFseparate reaction mixtures. The specificity of a parinjection, and ventricular tissue samples were harticular band representing NF-B DNA-binding acvested. tivity was verified by the ability of the consensus NF-B oligonucleotide to reduce or abrogate that band (specific competition), and the inability of the mutated oligonucleotide to do so while competing
Results
several non-specific complexes (non-specific competition) (Fig. 4) .
I B S32A,S36A transgenic mice
Of the 20 live-born mice obtained after pronuclear microinjection and embryo transplantation, five Studies of NF-B activation were identified as transgenic founders by PCR and confirmed by Southern blot analysis. The transgene In order to determine whether transdominant expression of I B S32A,S36A abrogates myocardial NFcopy numbers in these five lines were 1, 2, 4, 7 and 7. There were no obvious anatomical defects in the B activation in vivo, mice received i.p. injection of vehicle (sterile water), recombinant murine TNFheart or other organs as revealed by pathologic examination. We observed no macroscopic evidence of (rm-TNF-, Peprotech, Rocky Hill, NJ, USA) or LPS cardiac hypertrophy or cardiac morphologic an-III), TNF-completely failed to activate myocardial NF-B (Fig. 4) . Competition assays using probes conomaly in transgenic mice. The heart weight to body weight ratio (mg/g, mean±...) in transgenic taining the consensus and mutated NF-B binding sites confirmed the specificity of the DNA binding mice (4.10±0.28; n=4) was not significantly different from that in NTg mice (4.55±0.11; n=4, P= activity for the NF-B site (Fig. 4) . NS by Student's t-test) . 35 There was no abnormality in size of cardiac chambers. We observed no unusual LPS stimulation pre-or post-natal lethality attributable to the transgene.
EMSA performed using nuclear extracts from NTg mice after LPS administration (group IV) demonstrated myocardial NF-B DNA-binding activity Histologic examination (Fig. 4) . Activation of myocardial NF-B in response to LPS stimulation was, within the limits of Microscopic examination of ventricular tissue sections stained with hematoxylin and eosin did not detection of the assay, abrogated in I B S32A,S36A transgenic mice (group V, Fig. 4 ). reveal any abnormality in the transgenic relative to NTg mice (Fig. 2) . There was no evidence of right or left ventricular dilatation or wall thickening, inTime-course of NF-B activation cluding the interventricular septum. Similarly, we observed no cellular disarray, myocyte hypertrophy, As shown above, we detected a robust induction of NF-B DNA-binding activity 30 min after TNF-adabnormal size or shape of nuclei or abnormal cardiac vasculature. Examination of tissue sections stained ministration (group II, Fig. 4 ). EMSA performed using nuclear extracts from NTg mice after similar with Masson's trichrome stain revealed no evidence of pathologic fibrosis in the myocardium or entreatment demonstrated a time-dependent decrease in the intensity of myocardial NF-B activation at docardium of hearts from transgenic mice (Fig. 2) . 1 h, 3 h, and 6 h (groups VI, VIII and X, respectively, Fig. 5 ). The NF-B DNA binding activity was nearly undetectable in NTg mice 6 h after TNF-injection Myocardial I B protein content (group X). There was no detectable NF-B DNA-binding activity at any time-point in the I B S32A,S36A tranQuantitative analysis of Western blots demonstrated that the total amount of myocardial I B protein sgenic mice. was increased 3.5-to 6.5-fold in transgenic relative to NTg mice (Fig. 3 ). There was a concomitant 50-Supershift assays 60% decrease in the levels of myocardial I B in all lines (Fig. 3) .
Supershift assays using antibodies against the p65 component of NF-B identified p65 as one of the components of the NF-B DNA-binding complex activated in response to TNF-stimulation in the myoAbrogation of myocardial NF-B activation cardium (Fig. 6) . Two different agents (TNF-and LPS) known to be potent activators of NF-B were used to determine whether transgenic expression of the mutant
Discussion

I B
S32A,S36A blocks activation of NF-B in the myocardium.
NF-B, a pleiotropic transcription factor first identified as a regulator of the expression of the kappa light-chain gene in murine B lymphocytes, 36 has TNF-stimulation been implicated in the signal transduction pathways underlying various cardiac pathophysiologic states, EMSA performed using nuclear extracts of ventricular tissue from NTg mice after i.p. injection of including ischemic preconditioning, congestive heart failure, unstable angina pectoris, atherosterile water (group I) failed to demonstrate any detectable NF-B DNA binding activity, confirming genesis, and apoptosis. 6-9,11 However, unequivocal determination of a role of NF-B in pathophysiologic that the vehicle or the i.p. injection itself does not activate NF-B in the heart (Fig. 4) . A robust acprocesses requires specific inhibition of the transcription factor in the heart in vivo, which thus far tivation of NF-B was observed in the myocardium of NTg mice after TNF-administration (group II).
has not been possible. As a result, the contribution of NF-B to cardiovascular pathophysiology in the In contrast, in I B S32A,S36A transgenic mice (group Figure 2 Histologic examination of the I B S32A,S36A transgenic mouse hearts. Cross-sections of transgenic mouse hearts (hematoxylin and eosin stain, panel B, ×4 magnification) did not show any evidence of chamber dilatation and free wall or septal thickening compared to the non-transgenic mouse heart (panel A). No cellular disarray, excessive fibrosis or abnormal vascularity was evident in the transgenic mouse heart (Masson's trichrome stain, ×100 magnification, panel D) compared to the non-transgenic heart (panel C). Nuclear shape and size, nuclear-cytoplasmic ratio, and overall cellular structure appeared normal in the transgenic hearts (hematoxylin and eosin, ×400 magnification, panel F) compared to the non-transgenic hearts (panel E). ) showed robust activation of NF-B in the heart. In contrast, both TNF-(group III) and LPS (group V) failed to induce any NF-B DNA binding in the myocardium of transgenic mice, indicating that transgenic expression of I B S32A,S36A completely abrogated activation of all NF-B subunits in the myocardium. The specificity of the myocardial NF-B DNA binding activity was verified by specific competition with a 100-fold excess of (NF-B consensus sequence) probe.
Figure 5
Time-course of myocardial NF-B activation following rm-TNF-stimulation by electrophoretic mobility shift assay. Mice were euthanized 1 h (groups VI and VII), 3 h (groups VIII and IX), or 6 h (groups X and XI) after rm-TNFadministration. Myocardial nuclear extracts from non-transgenic (NTg) mice (groups VI, VIII and X) showed detectable activation of NF-B at all time-points, though the intensity of activation decreased over time with only minimal activation detectable at 6 h (group X). In contrast, rm-TNF-failed to activate NF-B in the myocardium of transgenic (Tg) mice at all time-points, indicating that the transgenic blockade of NF-B activation persisted for at least 6 h, and that there was no delayed activation of NF-B in transgenic mice. intact animal has been inferred either from correlative evidence (e.g., association of NF-B activation with a certain outcome) or by inhibition with pharmacologic agents of limited specificity. 12, 13 The present study demonstrates that cardiac-specific expression of a transdominant I B S32A,S36A is effective in completely abrogating NF-B activation in mice without apparent effects on cardiac morphology and histology, or on viability. To our knowledge, this is the first transgenic mouse with in vivo repression of NF-B in a cardiac-specific manner.
Viability of I B
S32A,S36A transgenic mice adult murine heart is currently unknown. Thus, to the nucleus in the heart of NTg mice in response to TNF-stimulation is p65.
combining multiple specific knockouts of NF-B subunits to abrogate NF-B activity in the heart is not feasible. In order to circumvent these problems, in time-course studies demonstrated no subsequent NF-B activation in transgenic mice (Fig. 5) . These the present study we used a different approach, i.e., cardiac-specific transdominant inhibition of NF-B results confirm that phosphorylation of serine residues at positions 32 and 36 of I B is critical for the signaling. Our results indicate that mice bearing a cardiac-specific transgene encoding a transregulation of NF-B activation, and that this mechanism is operative in the murine heart. This also dominant I B S32A,S36A are viable and fertile, at least at the levels of expression examined here. Furproves, for the first time, that blockade of activation of all NF-B subunits expressed in the heart is possible thermore, while achieving what is essentially a functional knockout of NF-B in the heart, there appear in vivo by expressing the phosphorylation-resistant mutant I B S32A,S36A
. Furthermore, since theto be no obvious deleterious pathophysiologic effects of transgene expression. Because we did not obtain
MyHC promoter drives gene expression only in cardiac myocytes, 22 our results imply that TNFtransgenic founders with transgene copy numbers higher than seven, we cannot rule out the possibility activates NF-B predominantly in cardiac myocytes which comprise only approximately 25% of all myothat mice having higher copy numbers were inviable. Even if high copy numbers of the I B S32A,S36A cardial cells. 38 This finding has profound implications for the action of TNF-upon the heart. transgene were associated with deleterious phenotypes, this would not seriously impinge upon the utility of these mice, since our data demonstrate that the low copy number lines studied herein result in Myocardial I B protein expression complete inhibition of NF-B activation in the heart. However, further studies are needed to address Interestingly, we noted a 50-60% decrease in the levels of myocardial I B protein in I B S32A,S36A
whether expression of I B S32A,S36A results in nonspecific effects on activation/inhibition of Rel homtransgenic mice (Fig. 3 ). This would be expected if I B is a B-dependent gene as has been demology domain transcription factors other than NF-B. onstrated for I B , I B , and I BL. [39] [40] [41] [42] Kontgen et al. 16 concluded that I B is not a B-dependent gene based upon the observation that I B transcript levels were not increased in cultured murine pre-B Myocardial I B protein expression cells 12 h after NF-B activation. Our results show that I B protein levels are reduced by chronic supWestern blot analyses, using an antibody directed against a carboxy terminal epitoph that is conserved pression of NF-B activation in the heart and are consistent with NF-B regulation of I B . Other inbetween mouse and human I B , demonstrated an increase in the total level of I B in the heart. In terpretations of our observation that I B levels are reduced in I B S32A,S36A transgenic mice are certainly underloaded lanes we can identify the mutant I B by its altered mobility relative to the endogenous possible, for example, enhanced degradation of I B due to its displacement from NF-B by mutant I B . I B (data not shown). Thus, the increase is attributed to the expression of the mutant I B S32A,S36A Direct demonstration that I B is transcriptionally regulated by NF-B awaits further experimentation. in the myocardium of transgenic mice. Quantitative analysis revealed that the total myocardial I B proOur results in transgenic mice, Kontgen's in cultured cells, as well as the persistent (late) activation of NFtein levels in transgenic mice were 3.5-to 6.5-fold higher than the endogenous I B levels in NTg mice.
B that has been observed in mouse, 16 rat, 43, 44 and human cells 45 could all be explained by an extremely slow (>12 h) transcriptional response of the I B gene. There is evidence that differential degradation Abrogation of myocardial NF-B activation in response to TNF-and LPS of I B relative to I B is the basis of the persistent NF-B activation in human and rat 44, 46 and there is TNF-and LPS are two of the most potent activators evidence that one of the two human I B isoforms, I B 2, mediates persistent NF-B activation via its of NF-B known to exist. Our EMSA analysis demonstrates that both TNF-and LPS activate NF-B degradation kinetics (slow). 47 Interestingly, the single murine I B isoform closely resembles human in the hearts of NTg mice and that this activation, within the limitations of the assay, is completely ab-I B 1, which has degradation kinetics similar to I B (fast). 47 That I B and I B in the mouse are rogated in the myocardium of I B S32A,S36A transgenic mice (Fig. 4) . The failure of TNF-and LPS to functionally interchangeable is supported by recent gene replacement experiments in which the I B activate NF-B at 30 min after the stimulus was not simply due to a delay in NF-B activation, since our protein coding region was replaced by I B and the kinetics of NF-B activation was found to be unmyocardial ischemia-reperfusion injury, heart failure, septic shock, cardiac hypertrophy, atheroaltered. 48 There is evidence that I B and I B have different association constants for NF-B. 49 Thus, in genesis, acute coronary syndromes, and cardiac allograft rejection. the mouse, prolongation of NF-B activation may be mediated in part by the differing association constants of individual I B isoforms, and in part by transcriptional regulation of I B genes. Although
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approach obviates the lack of specificity that limits 
